Table 1.
Clinical Characteristics of NSCLC Patients
| Patients | Patients | ||||
|---|---|---|---|---|---|
| characteristics | Stratification | n (%) | characteristics | Stratification | n (%) |
| Total no. of patients | 445 | Gender | |||
| Median age (range) | 57 (32–80) | Male | 317 (71.2) | ||
| ≤57 | 226 (50.8) | Female | 128 (28.8) | ||
| >57 | 219 (49.2) | TNM stage | |||
| PS | ⅢA | 43 (9.7) | |||
| 0–1 | 427 (96.0) | ⅢB | 131 (29.4) | ||
| 2 | 17 (4.0) | Ⅳ | 271 (60.9) | ||
| Anemia | Chemotherapy regimen | ||||
| Grade 1 or 2 | 391 (87.9) | Platinum‐navelbine | 233 (52.4) | ||
| Grade 3 or 4 | 22 (4.9) | Platinum‐gemcitabine | 77 (17.3) | ||
| Thrombocytopenia | Platinum‐paclitaxel | 90 (20.2) | |||
| Grade 1 or 2 | 392 (88.1) | Platinum‐docetaxel | 22 (4.9) | ||
| Grade 3 or 4 | 26 (5.8) | Other platinum combinations | 23 (5.2) | ||
| ORR | Platinum‐based drug | ||||
| CR or PR | 76 (17.1) | Cisplatin | 326 (73.3) | ||
| SD or PD | 342 (76.9) | Carboplatin | 119 (26.7) | ||
| Leukocytopenia | Histological type | ||||
| Grade 1 or 2 | 326 (73.3) | Adenocarcinoma | 269 (60.5) | ||
| Grade 3 or 4 | 104 (23.4) | Squamous cell | 88 (19.8) | ||
| Neutropenia | Adenosquamocarcinoma | 16 (3.6) | |||
| Grade 1 or 2 | 340 (76.4) | Othersa | 72 (16.2) | ||
| Grade 3 or 4 | 65 (14.6) | Overall toxicity | |||
| Hematologic toxicity | Grade 1 or 2 | 240 (53.9) | |||
| Grade 1 or 2 | 273 (61.4) | Grade 3 or 4 | 142 (31.9) | ||
| Grade 3 or 4 | 129 (29.0) | rs11614913 | |||
| Gastrointestinal toxicity | CC | 134 (30.1) | |||
| Grade 1 or 2 | 376 (84.5) | CT | 225 (50.6) | ||
| Grade 3 or 4 | 27 (6.1) | TT | 83 (18.7) |
a
Other carcinomas include mixed cell, neuroendocrine carcinoma, or undifferentiated carcinoma.
NSCLC, nonsmall cell lung cancer; TNM, tumor/node/metastasis; PS, performance status; ORR, objective response rate; CR, complete response; PR, partial response; SD, stable disease; PD, progressive disease.